REG - Cambridge Cognition - £2.1 million contracts for rare disease trials

Cambridge Cognition HoldingsAnnouncement

12/04/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230412:nRSL8846Va&default-theme=true

RNS Number : 8846V  Cambridge Cognition Holdings PLC  12 April 2023

Cambridge Cognition Holdings Plc

 

("Cambridge Cognition" or the "Company")

 

Cambridge Cognition awarded two contracts worth £2.1 million for rare disease
trials

 

Cambridge Cognition (AIM: COG), which develops and markets digital solutions
to assess brain health, is pleased to announce that it has won two sizeable
contracts, together worth over £2.1 million, to provide the Company's
CANTAB® cognitive assessments and electronic Clinical Outcome Assessments
("eCOA") for two pivotal trials involving patients with a rare disease. The
contracts have been awarded by a new customer for the Company with revenues
expected to be recognised over the next five years.

A rare disease is a condition that affects fewer than one in 2,000 people
within the general population. While each individual disease may only affect a
small amount of people, collectively, rare diseases affect about 6-8% of the
population. Rare diseases are often associated with neurodevelopmental issues
and cognitive dysfunction. Cambridge Cognition are widely recognised for
proprietary cognitive assessments (CANTAB®) that are sensitive to the
specific neural pathways impacted by disorders and improved by therapeutics.
The Company therefore provides a valuable solution for pharmaceutical
companies developing new drugs for a rare disease that may help improve the
patient's cognitive function.

Every clinical trial includes questionnaires and is seeking a seamless
experience for both patient and site. Recognising this need, Cambridge
Cognition offers both eCOA and cognitive assessments in a single, easy-to-use
platform. This unique product offering combined with the Company's extensive
multi-site, multi-country project management experience secured Cambridge
Cognition these two pivotal trials with a new customer.

Participation in these trials will enable Cambridge Cognition to offer more
insights into the use of digital cognitive assessments and eCOA solutions as
part of rare disease trials, including how effective these methods are for use
in long-term studies.

Commenting, Matthew Stork, Chief Executive Officer of Cambridge Cognition,
said: "Over the past five years Cambridge Cognition has developed a unique
offering for clinical trials of leading cognitive assessments (CANTAB®) and
electronic questionnaires (eCOA) in a single, easy-to-use platform. This,
combined with our reputation for outstanding customer service and cutting-edge
science, has enabled us to secure two large contracts with a new customer.
These contracts will strengthen our presence in the rare disease field and
showcase how our cognitive assessments can be used effectively in the
development of symptom modifying treatments."

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) No 596/2014 as it forms part of UK law by virtue of the
European Union (Withdrawal) Act 2018.

Enquiries

 

 Cambridge Cognition Holdings Plc                         Tel: 012 2381 0700 

 Matthew Stork, Chief Executive Officer                   press@camcog.com (mailto:press@camcog.com)  

 Stephen Symonds, Chief Financial Officer

 Panmure Gordon (UK) Limited (NOMAD and Joint Broker)     Tel: 020 7886 2500 

 Freddy Crossley / Emma Earl                              (Corporate Finance) 

 Rupert Dearden                                           (Corporate Broking) 

 Dowgate Capital Limited (Joint Broker)                   Tel: 020 3903 7715 

 David Poutney / James Serjeant                            

 IFC Advisory Ltd (Financial PR and IR)                   Tel: 020 3934 6630 

 Tim Metcalfe / Graham Herring / Zach Cohen                cog@investor-focus.co.uk

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products
to better understand, detect and treat conditions affecting brain health. The
Company's software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com
(http://www.cambridgecognition.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTDFLFFXZLLBBD